当前位置: X-MOL 学术N. Engl. J. Med. › 论文详情
Trial of Apremilast for Oral Ulcers in Behçet’s Syndrome
The New England Journal of Medicine ( IF 70.670 ) Pub Date : 2019-11-14 , DOI: 10.1056/nejmoa1816594
Gülen Hatemi; Alfred Mahr; Yoshiaki Ishigatsubo; Yeong-Wook Song; Mitsuhiro Takeno; Doyoung Kim; Melike Melikoğlu; Sue Cheng; Shannon McCue; Maria Paris; Mindy Chen; Yusuf Yazici

Background The small-molecule phosphodiesterase 4 inhibitor apremilast modulates cytokines that are up-regulated in Behçet’s syndrome. In a phase 2 trial involving patients with Behçet’s syndrome, apremilast reduced the incidence and severity of oral ulcers. Data on the efficacy and safety of apremilast in patients with Behçet’s syndrome who had active oral ulcers and had not previously received biologic agents are limited. Methods In a phase 3 trial, we randomly assigned, in a 1:1 ratio, patients who had Behçet’s syndrome with active oral ulcers but no major organ involvement to receive either apremilast at a dose of 30 mg or placebo, administered orally, twice daily for 12 weeks, followed by a 52-week extension phase. The primary end point was the area under the curve (AUC) for the total number of oral ulcers during the 12-week placebo-controlled period (with lower values indicating fewer ulcers). There were 13 secondary end points, including complete response of oral ulcers, change from baseline in pain associated with oral ulcers, disease activity, and change from baseline in the Behçet’s Disease Quality of Life score (range, 0 to 30, with higher scores indicating greater impairment in quality of life). Safety was also assessed. Results A total of 207 patients underwent randomization (104 patients to the apremilast group and 103 to the placebo group). The AUC for the number of oral ulcers was 129.5 for apremilast, as compared with 222.1 for placebo (least-squares mean difference, −92.6; 95% confidence interval [CI], −130.6 to −54.6; P<0.001). The change from baseline in the Behçet’s Disease Quality of Life score was −4.3 points in the apremilast group, as compared with −1.2 points in the placebo group (least-squares mean difference, −3.1 points; 95% CI, −4.9 to −1.3). Adverse events with apremilast included diarrhea, nausea, and headache. Conclusions In patients with oral ulcers associated with Behçet’s syndrome, apremilast resulted in a greater reduction in the number of oral ulcers than placebo but was associated with adverse events, including diarrhea, nausea, and headache. (Funded by Celgene; ClinicalTrials.gov number, NCT02307513.) VISUAL ABSTRACT Apremilast for Oral Ulcers in Behçet’s Syndrome
更新日期:2019-11-14

 

全部期刊列表>>
全球疫情及响应:BMC Medicine专题征稿
欢迎探索2019年最具下载量的化学论文
新版X-MOL期刊搜索和高级搜索功能介绍
化学材料学全球高引用
ACS材料视界
南方科技大学
x-mol收录
南方科技大学
自然科研论文编辑服务
上海交通大学彭文杰
中国科学院长春应化所于聪-4-8
武汉工程大学
课题组网站
X-MOL
深圳大学二维材料实验室张晗
中山大学化学工程与技术学院
试剂库存
天合科研
down
wechat
bug